Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes, working as a dual GLP-1/GIP receptor agonist that targets both the GLP-1 and GIP receptors instead of GLP-1 alone, which enhances fat metabolism and insulin sensitivity beyond a single-receptor peptide
Mass spec confirms the molecular weight matches the exact peptide sequence claimed on the label proving it is what it says it is, not a cheaper substitute
Despite years of safe compounding, established protocols, and satisfied patients, Category 2 designation meant immediate cessation
IGF-1 LR3 has an extended half-life compared to native IGF-1, making it more effective at stimulating anabolic processes
Clinics generally advise against starting treatment for anyone who: Is pregnant Has a personal or family history of thyroid cancer Has a history of multiple endocrine neoplasia (MEN) syndrome BMI and health history serve as a useful starting point for this evaluation, not an absolute cutoff, since metabolism and overall wellness also weigh into a provider's decision
Journal of Clinical Investigation, 116 (7), 1776-1783